GLP-1 drugs, including Wegovy, Zepbound, and Foundayo, help patients lose weight by mimicking a hormone that makes the body ...

Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 ...

Berenberg Bank analyst Kerry Holford reiterated a Hold rating on GlaxoSmithKline today and set a price target of p2,200.00. According to TipRanks, Holford is a 4-star analyst with an average return of ...

Diageo agreed in June 2024 to sell its majority stake in Guinness Nigeria to the Tolaram group, a deal that closed the ...

GSK will acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences in a deal worth up to $750 ...

AstraZeneca received a Hold rating and an £117.00 price target from Deutsche Bank analyst Emmanuel Papadakis today. Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, ...

Nigeria’s corporate exodus story is now familiar, with ride-hailing app Uber’s September 2nd exit, after twelve years in the market, the latest. Recently, hypermarket giant Shoprite has wound down its ...

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens ...

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at ...

GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid what a spokesperson said is ...

GSK trades at GBX1,860.50 today, up 0.4%. Key technicals highlight sideways movement and volatility in the short term.

Berenberg analyst Kerry Holford upgraded GlaxoSmithKline (NYSE: GSK) from Hold to Buy with a price target of $60.00 (from $54.00). For an analyst ratings summary and ratings ...